title: The effects of propofol on cardiac function after 4 hours of cold cardioplegia and reperfusion.
abstract: OBJECTIVE
  To examine whether propofol protects against postischemic myocardial dysfunction and apoptosis during reperfusion after prolonged cold ischemia in isolated rat hearts.
  
  
  METHODS
  A prospective, randomized, controlled study.
  
  
  METHODS
  A university laboratory.
  
  
  METHODS
  Animals.
  
  
  METHODS
  The isolated hearts of 40 Sprague-Dawley male rats were perfused with modified Krebs-Hennseleit solution for 15 minutes for a stabilization period and 15 minutes for a perfusion period and then underwent 4 hours of global cold ischemia followed by 60 minutes of reperfusion. Four groups were studied (n = 10 for each group). Ten hearts served as an untreated control group. Propofol (2 micromol/L) treatment was performed only before ischemia in the PRE group, only during reperfusion in the POST group, and both before and after ischemia in the ALL group.
  
  
  RESULTS
  Infusion of propofol during reperfusion improved recovery of left ventricular-developed pressure (LVDP) from 61.2% +/- 8.5% (control) to 86.3% +/- 12.1% (POST) and 74.9% +/- 13.2% (ALL, both p < 0.05), whereas preischemic infusion of propofol (64.3% +/- 9.7%, PRE) did not improve recovery of LVDP. Infusion of propofol during reperfusion significantly reduced the number of apoptotic cells and led to a smaller infarct size than control and PRE groups (p < 0.05, respectively).
  
  
  CONCLUSIONS
  Propofol infusion during the reperfusion period produced a cardioprotective effect and inhibited apoptosis of cardiomyocytes in the ischemia-reperfusion model, with prolonged cold ischemia, in isolated rat hearts.
authors: Department of Anesthesiology and Pain Medicine, Korea University Anam Hospital, Seoul, Korea.
authors: Sung Uk
authors: SU
authors: Choi
authors: Hye Won
authors: HW
authors: Lee
authors: Hae Ja
authors: HJ
authors: Lim
authors: Suk Min
authors: SM
authors: Yoon
authors: Seong Ho
authors: SH
authors: Chang
mesh_terms: D018686:Anesthetics, Intravenous / Q000494:pharmacology*; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D001920:Bradykinin / Q000008:administration & dosage; D003331:Coronary Vessels; D005947:Glucose; D006321:Heart / Q000187:drug effects* / Q000502:physiology; D006324:Heart Arrest, Induced / Q000379:methods; D008297:Male; D009203:Myocardial Infarction / Q000473:pathology / Q000517:prevention & control; D015425:Myocardial Reperfusion / Q000379:methods; D015742:Propofol / Q000494:pharmacology*; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D015427:Reperfusion Injury / Q000517:prevention & control; D013997:Time Factors; D014325:Tromethamine; D014665:Vasodilator Agents / Q000008:administration & dosage; D017725:Ventricular Pressure / Q000187:drug effects
chemical_list: D018686:Anesthetics, Intravenous; C074097:Krebs-Henseleit solution; D014665:Vasodilator Agents; D014325:Tromethamine; D005947:Glucose; D001920:Bradykinin; D015742:Propofol